The ESMO Advanced Course on Precision Medicine for Patients with HR+ HER2- Advanced Breast Cancer: Testing, Selecting, Treating 2026: Zurich is a two-day course for experienced oncologists and specialists, focusing on using precision medicine to manage patients with HR-positive, HER2-negative metastatic breast cancer.

The event is scheduled to take place on March 4–5, 2026, in Zurich, Switzerland.

The application deadline for participation is January 7, 2026, at 23:59 CET. The course objectives include understanding the rationale and technical background of biomarker testing, using results for optimal patient selection, and discussing the proactive management of precision-medicine-based treatments.

Apply.